nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—ADRB3—polycystic ovary syndrome	0.473	0.586	CbGaD
Clenbuterol—ADRB2—polycystic ovary syndrome	0.18	0.223	CbGaD
Clenbuterol—CYP1A1—polycystic ovary syndrome	0.154	0.191	CbGaD
Clenbuterol—TNF—vagina—polycystic ovary syndrome	0.00241	0.134	CbGeAlD
Clenbuterol—NGF—adrenal gland—polycystic ovary syndrome	0.0024	0.133	CbGeAlD
Clenbuterol—NGF—female gonad—polycystic ovary syndrome	0.00224	0.124	CbGeAlD
Clenbuterol—CYP1A2—urine—polycystic ovary syndrome	0.00214	0.119	CbGeAlD
Clenbuterol—NGF—endocrine gland—polycystic ovary syndrome	0.00208	0.116	CbGeAlD
Clenbuterol—ADRB3—adipose tissue—polycystic ovary syndrome	0.00171	0.0947	CbGeAlD
Clenbuterol—Bupranolol—ADRB3—polycystic ovary syndrome	0.00164	0.279	CrCbGaD
Clenbuterol—ADRB3—female gonad—polycystic ovary syndrome	0.00143	0.0792	CbGeAlD
Clenbuterol—Bambuterol—ADRB2—polycystic ovary syndrome	0.00128	0.217	CrCbGaD
Clenbuterol—Pirbuterol—ADRB2—polycystic ovary syndrome	0.000969	0.164	CrCbGaD
Clenbuterol—Terbutaline—ADRB2—polycystic ovary syndrome	0.00079	0.134	CrCbGaD
Clenbuterol—ADRB1—adipose tissue—polycystic ovary syndrome	0.000698	0.0387	CbGeAlD
Clenbuterol—Bupranolol—ADRB2—polycystic ovary syndrome	0.000624	0.106	CrCbGaD
Clenbuterol—Salbutamol—ADRB2—polycystic ovary syndrome	0.000587	0.0997	CrCbGaD
Clenbuterol—ADRB1—endocrine gland—polycystic ovary syndrome	0.000543	0.0301	CbGeAlD
Clenbuterol—CYP1A1—uterus—polycystic ovary syndrome	0.00046	0.0255	CbGeAlD
Clenbuterol—CYP1A1—adipose tissue—polycystic ovary syndrome	0.00045	0.025	CbGeAlD
Clenbuterol—CYP1A1—female gonad—polycystic ovary syndrome	0.000376	0.0209	CbGeAlD
Clenbuterol—CYP1A1—vagina—polycystic ovary syndrome	0.000374	0.0208	CbGeAlD
Clenbuterol—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000355	0.0197	CbGeAlD
Clenbuterol—CYP1A1—endocrine gland—polycystic ovary syndrome	0.00035	0.0194	CbGeAlD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	2.64e-05	0.000156	CbGpPWpGaD
Clenbuterol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—polycystic ovary syndrome	2.64e-05	0.000155	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	2.63e-05	0.000155	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	2.61e-05	0.000154	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.61e-05	0.000154	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	2.57e-05	0.000151	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—FGF18—polycystic ovary syndrome	2.57e-05	0.000151	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	2.56e-05	0.000151	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	2.55e-05	0.00015	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—RBP4—polycystic ovary syndrome	2.55e-05	0.00015	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—IL6—polycystic ovary syndrome	2.53e-05	0.000149	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	2.51e-05	0.000148	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.51e-05	0.000148	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	2.49e-05	0.000147	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	2.49e-05	0.000147	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	2.47e-05	0.000146	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.47e-05	0.000145	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—LEP—polycystic ovary syndrome	2.46e-05	0.000145	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	2.42e-05	0.000143	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	2.41e-05	0.000142	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—YAP1—polycystic ovary syndrome	2.38e-05	0.00014	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	2.36e-05	0.000139	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	2.35e-05	0.000138	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—GAB1—polycystic ovary syndrome	2.35e-05	0.000138	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	2.34e-05	0.000138	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	2.31e-05	0.000136	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—CYP1A1—polycystic ovary syndrome	2.3e-05	0.000136	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—AKR1C2—polycystic ovary syndrome	2.3e-05	0.000135	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—TEAD2—polycystic ovary syndrome	2.3e-05	0.000135	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	2.3e-05	0.000135	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IRS2—polycystic ovary syndrome	2.29e-05	0.000135	CbGpPWpGaD
Clenbuterol—CYP1A2—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	2.27e-05	0.000134	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—LEP—polycystic ovary syndrome	2.24e-05	0.000132	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—INSR—polycystic ovary syndrome	2.24e-05	0.000132	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.21e-05	0.00013	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	2.19e-05	0.000129	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.18e-05	0.000128	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	2.14e-05	0.000126	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—PPARG—polycystic ovary syndrome	2.14e-05	0.000126	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	2.14e-05	0.000126	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.13e-05	0.000125	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	2.12e-05	0.000125	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—INS—polycystic ovary syndrome	2.1e-05	0.000124	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.1e-05	0.000123	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	2.09e-05	0.000123	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PGR—polycystic ovary syndrome	2.08e-05	0.000122	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—AKT2—polycystic ovary syndrome	2.03e-05	0.000119	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—NMNAT3—polycystic ovary syndrome	2.03e-05	0.000119	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IRS1—polycystic ovary syndrome	2e-05	0.000118	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	1.99e-05	0.000117	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	1.95e-05	0.000115	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	1.95e-05	0.000115	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.94e-05	0.000114	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	1.93e-05	0.000114	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—GHRL—polycystic ovary syndrome	1.93e-05	0.000114	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PLAT—polycystic ovary syndrome	1.93e-05	0.000114	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—POMC—polycystic ovary syndrome	1.93e-05	0.000114	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PNPLA2—polycystic ovary syndrome	1.93e-05	0.000113	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—INS—polycystic ovary syndrome	1.92e-05	0.000113	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	1.91e-05	0.000112	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.9e-05	0.000112	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	1.89e-05	0.000111	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.88e-05	0.00011	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.86e-05	0.000109	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IGF1—polycystic ovary syndrome	1.85e-05	0.000109	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—LPCAT2—polycystic ovary syndrome	1.85e-05	0.000109	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—SUOX—polycystic ovary syndrome	1.85e-05	0.000109	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—AKT2—polycystic ovary syndrome	1.85e-05	0.000109	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ATF1—polycystic ovary syndrome	1.84e-05	0.000108	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.83e-05	0.000108	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	1.83e-05	0.000108	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—SRD5A1—polycystic ovary syndrome	1.83e-05	0.000108	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.82e-05	0.000107	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.8e-05	0.000106	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.79e-05	0.000105	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.78e-05	0.000105	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	1.78e-05	0.000105	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.77e-05	0.000104	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.76e-05	0.000104	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.76e-05	0.000103	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—STAR—polycystic ovary syndrome	1.74e-05	0.000103	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	1.74e-05	0.000102	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	1.74e-05	0.000102	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	1.72e-05	0.000101	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.72e-05	0.000101	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	1.72e-05	0.000101	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.72e-05	0.000101	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—NGFR—polycystic ovary syndrome	1.7e-05	0.0001	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	1.7e-05	0.0001	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.7e-05	9.99e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—POMC—polycystic ovary syndrome	1.69e-05	9.94e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	1.68e-05	9.92e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PRL—polycystic ovary syndrome	1.68e-05	9.92e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.66e-05	9.77e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.64e-05	9.67e-05	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.64e-05	9.65e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	1.63e-05	9.57e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.62e-05	9.56e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.61e-05	9.46e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.61e-05	9.45e-05	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.6e-05	9.44e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.6e-05	9.41e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	1.59e-05	9.37e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	1.57e-05	9.26e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—HMMR—polycystic ovary syndrome	1.55e-05	9.14e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.55e-05	9.13e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	1.52e-05	8.98e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.52e-05	8.94e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	1.51e-05	8.9e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.49e-05	8.79e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	1.49e-05	8.78e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.49e-05	8.77e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—GNAS—polycystic ovary syndrome	1.48e-05	8.72e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—HSD3B1—polycystic ovary syndrome	1.48e-05	8.72e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	1.48e-05	8.71e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	1.47e-05	8.63e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	1.47e-05	8.63e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.46e-05	8.62e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.46e-05	8.57e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.41e-05	8.31e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	1.41e-05	8.31e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.41e-05	8.3e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	1.39e-05	8.2e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.39e-05	8.17e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—NRG1—polycystic ovary syndrome	1.39e-05	8.16e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	1.38e-05	8.13e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	1.36e-05	8.02e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—LHB—polycystic ovary syndrome	1.35e-05	7.95e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	1.33e-05	7.84e-05	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—VEGFA—polycystic ovary syndrome	1.33e-05	7.81e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—HSD3B2—polycystic ovary syndrome	1.32e-05	7.77e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	1.3e-05	7.67e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—AKR1C1—polycystic ovary syndrome	1.28e-05	7.53e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.26e-05	7.45e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.24e-05	7.33e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.24e-05	7.28e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	1.23e-05	7.26e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	1.23e-05	7.23e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.22e-05	7.17e-05	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.21e-05	7.13e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	1.21e-05	7.1e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IRS2—polycystic ovary syndrome	1.19e-05	6.99e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—SULT2A1—polycystic ovary syndrome	1.18e-05	6.93e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	1.16e-05	6.86e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—LEP—polycystic ovary syndrome	1.16e-05	6.84e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.15e-05	6.75e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.15e-05	6.75e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	1.14e-05	6.71e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	1.12e-05	6.6e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	1.12e-05	6.6e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	1.11e-05	6.54e-05	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.1e-05	6.5e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	1.1e-05	6.47e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.1e-05	6.46e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.09e-05	6.44e-05	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.08e-05	6.36e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.07e-05	6.3e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.07e-05	6.28e-05	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.06e-05	6.25e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	1.06e-05	6.21e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.05e-05	6.18e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.04e-05	6.14e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	1.04e-05	6.14e-05	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.04e-05	6.11e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.04e-05	6.1e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.03e-05	6.09e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.01e-05	5.94e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	1e-05	5.9e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	1e-05	5.89e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	9.98e-06	5.87e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	9.92e-06	5.84e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	9.9e-06	5.83e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	9.87e-06	5.81e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	9.84e-06	5.8e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	9.81e-06	5.77e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	9.78e-06	5.76e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	9.69e-06	5.71e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.63e-06	5.67e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	9.6e-06	5.65e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	9.59e-06	5.65e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.48e-06	5.58e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	9.45e-06	5.56e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.42e-06	5.55e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	9.34e-06	5.5e-05	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—IL6—polycystic ovary syndrome	9.17e-06	5.4e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.11e-06	5.37e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	8.85e-06	5.21e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	8.79e-06	5.18e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	8.61e-06	5.07e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	8.6e-06	5.07e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	8.42e-06	4.96e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—TH—polycystic ovary syndrome	8.39e-06	4.94e-05	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IL6—polycystic ovary syndrome	8.38e-06	4.93e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.38e-06	4.93e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	8.22e-06	4.84e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.2e-06	4.82e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	8.16e-06	4.8e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	8.15e-06	4.8e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	8.04e-06	4.74e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	7.67e-06	4.52e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	7.5e-06	4.42e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	7.34e-06	4.32e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	7.27e-06	4.28e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	7.04e-06	4.15e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	7.01e-06	4.12e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	6.89e-06	4.06e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	6.89e-06	4.06e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	6.85e-06	4.03e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	6.74e-06	3.97e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	6.73e-06	3.96e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.69e-06	3.94e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	6.65e-06	3.91e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.6e-06	3.89e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	6.52e-06	3.84e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	6.28e-06	3.7e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.27e-06	3.69e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	6.18e-06	3.64e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.15e-06	3.62e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	6.01e-06	3.54e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	5.92e-06	3.49e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	5.89e-06	3.47e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	5.79e-06	3.41e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	5.76e-06	3.39e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	5.76e-06	3.39e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.7e-06	3.35e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.69e-06	3.35e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	5.57e-06	3.28e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	5.57e-06	3.28e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.41e-06	3.18e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—TH—polycystic ovary syndrome	5.35e-06	3.15e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.29e-06	3.12e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	5.2e-06	3.06e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	4.89e-06	2.88e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	4.67e-06	2.75e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	4.61e-06	2.71e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—INS—polycystic ovary syndrome	4.58e-06	2.7e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	4.36e-06	2.57e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.36e-06	2.56e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	4.34e-06	2.55e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	4.26e-06	2.51e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	4.16e-06	2.45e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	3.94e-06	2.32e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.72e-06	2.19e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	3.67e-06	2.16e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.64e-06	2.14e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.98e-06	1.75e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.94e-06	1.73e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.92e-06	1.72e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	2.57e-06	1.51e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	2.52e-06	1.48e-05	CbGpPWpGaD
